title: [Vascular nephropathies: a fresh look at a systemic disease].
abstract: Hypertensive nephropathy represents the most prevalent cause of end-stage renal disease in France. Renal lesions are unspecific. Nephroangiosclerosis diagnosis is overestimated due to non standardized clinical criteria and available histological analysis. Other factors than hypertension contribute to vascular lesions.MYH9 and APOL1 polymorphisms are strongly associated with kidney diseases including hypertensive nephropathy. Elevated blood pressure levels are associated with CKD progression. Treatment includes angiotensin blockers which have a synergic effect on blood pressure reduction and lowering urinary protein excretion with sodium restriction and diuretics.
authors.affiliation: AP-HP, hôpital Tenon, service de néphrologie et dialyses, 75020 Paris, France. jean-jacques.boffa@tnn.aphp.fr
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Boffa
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000075944:Apolipoprotein L1; D001053:Apolipoproteins / Q000235:genetics; D003937:Diagnosis, Differential; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D006977:Hypertension, Renal / Q000235:genetics; D006978:Hypertension, Renovascular / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D007674:Kidney Diseases / Q000188:drug therapy / Q000209:etiology*; D008075:Lipoproteins, HDL / Q000235:genetics; D020409:Molecular Motor Proteins / Q000235:genetics; D018995:Myosin Heavy Chains / Q000235:genetics; D009400:Nephrosclerosis / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology; D011110:Polymorphism, Genetic; D012077:Renal Artery / Q000473:pathology
chemical_list: C108666:APOL1 protein, human; D057911:Angiotensin Receptor Antagonists; D000075944:Apolipoprotein L1; D001053:Apolipoproteins; D008075:Lipoproteins, HDL; C103814:MYH9 protein, human; D020409:Molecular Motor Proteins; D018995:Myosin Heavy Chains